Suffering Novartis partner Conatus grabs the ax and packs it in on NASH after a series of setbacks
The NASH party is over at Novartis-backed Conatus. And this time they’re turning off the lights.
More than 2 years after Novartis surprised the biotech investment community with its $50 million upfront and promise of R&D support to partner with the little biotech on NASH — igniting a lightning strike for the share price — Conatus $CNAT is back with the latest bitter tale to tell about emricasan, which once inspired confidence at the pharma giant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.